The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Gilead Sciences
Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
 
Sattva Swarup Neelapu
Honoraria - Bio Ascend; Dava Oncology; Medscape; Physicans' Education Resource
Consulting or Advisory Role - Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Bristol-Myers Squibb; Celgene; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; Pharmacyclics; poseida therapeutics; Unum Therapeutics
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Dava Oncology; Kite/Gilead; Medscape; Merck; Novartis; Pfizer; Physicans' Education Resource; Precision Biosciences; Unum Therapeutics
 
Caron A. Jacobson
Other Relationship - Bayer; Humanigen; Kite, a Gilead company; Novartis; Pfizer; Precision Biosciences
 
Olalekan O. Oluwole
Consulting or Advisory Role - Bayer; Kite, a Gilead company; Pfizer; Spectrum Pharmaceuticals
Research Funding - Kite, a Gilead company
 
Javier Munoz
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - AstraZeneca; Bayer; Gilead Sciences; Kite, a Gilead company; Pharmacyclics/Janssen
 
Abhinav Deol
Consulting or Advisory Role - Agios; Kite/Gilead; Novartis
 
David Bernard Miklos
Honoraria - Sanofi; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Janssen; Janssen; Juno/Celgene; Kite, a Gilead company; Novartis; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adaptive Biotechnologies; Kite, a Gilead company; Novartis; Pharmacyclics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Pharmacyclics/Janssen; Sanofi
 
Nancy L. Bartlett
Consulting or Advisory Role - Pfizer
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Celgene; Forty Seven; Genentech; Gilead Sciences
Other Relationship - Acerta Pharma; Immune Design; Kite, a Gilead company; Merck; Millennium; Pharmacyclics
 
Ira Braunschweig
Speakers' Bureau - Kite, a Gilead company
 
Yizhou Jiang
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Gilead Sciences
 
Jenny J. Kim
Employment - Kite, a Gilead company
 
Lianqing Zheng
Employment - Kite, a Gilead company
 
John M. Rossi
No Relationships to Disclose
 
Frederick Lundry Locke
Consulting or Advisory Role - Cellular Biomedicine Group; Kite, a Gilead company; Novartis
Research Funding - FORMA Therapeutics